Merck & Co., Inc. And Sirna Therapeutics, Inc. Announce Expiration Of Hart-Scott-Rodino Waiting Period For The Proposed Acquisition Of Sirna By Merck

WHITEHOUSE STATION, N.J. & SAN FRANCISCO--(BUSINESS WIRE)--Merck & Co., Inc. (NYSE: MRK) and Sirna Therapeutics, Inc. (NASDAQ: RNAI) announced today that the federal regulatory antitrust waiting period expired for Merck & Co.’s approximately $1.1 billion acquisition of Sirna Therapeutics. On Oct. 30, 2006, Merck entered into a definitive agreement to acquire Sirna for $13 per share in an all-cash transaction.